Welcome > Support > Âü°íÀÚ·á  
 
 
E
 
±Ûº¸±â
¼º¸í ÆijªÁø     (Date : 2011-08-26 18:31:16)
Á¦¸ñ [³í¹®] [Microarray]Peptide nucleic acid-based (PNA) array for the antigenic discrimination of canine parvovirus
³»¿ë

Research in Veterinary Science 2011
DOI : 10.1016/j.rvsc.2011.06.003


Peptide nucleic acid-based (PNA) array for the antigenic discrimination of canine parvovirus

Dong-Jun An, Wooseog Jeong, Hye-Young Jeoung, Myoung-Heon Lee,
Jee-Yong Park, Ji-Ae Lim, Bong-Kyun Park

Abstract

A novel peptide nucleic acid (PNA)-based array was developed for use in ante-mortem antigenic typing discrimination in dogs with canine parvovirus (CPV). Cyclic benzothiazole-2-sulfonyl PNA monomers were synthesized that recognized GTA (CPV-2) and TAT (CPV-2a, -2b and -2c) at the nt 913-915 positions, and AAT (CPV-2 and CPV-2a), GAT (CPV-2b), and GAA (CPV-2c) at the nt 1276-1278 positions of the VP2 gene. The detection limits for aa 305 and aa 426 of the VP2 proteins belonging to the four CPV antigenic types were determined optically to be 40-2000 DNA copies, and the optimal cut-off fluorescence signaling value was fixed at 5000. The PNA array described here was developed from 135 field dog fecal specimens and had 89.8% (62/69) sensitivity and 90.4% (66/73) specificity compared with a real-time PCR using the TaqMan assay, a gold standard method. This CPV PNA array could be used together with MGB probe assays as an attractive novel tool for ante-mortem antigenic typing discrimination.

Keywords : CPV, PNA, MGB probe


 

 ¹øÈ£   Á¦¸ñ ÀÛ¼ºÀÚ ÆÄÀÏ Á¶È¸
   49           [³í¹®] [2016]Comparison of EGFR .. ÆijªÁø 28882
   48           [³í¹®] [2015]IDH Mutation Analys.. ÆijªÁø 65535
   47           [³í¹®] [2015]Low frequency of KR.. ÆijªÁø 29220
   46           [³í¹®] [2015]Simultaneous genoty.. ÆijªÁø 6078
   45           [³í¹®] [2014]Simultaneous diagno.. ÆijªÁø 20983
   44           [³í¹®] [2014]KRAS Mutation Detec.. ÆijªÁø 8133
   43           [³í¹®] [2013]Detection of EGFR m.. ÆijªÁø 1185
   42           [³í¹®] [2013]Detection and compa.. ÆijªÁø 5825
   41           [³í¹®] [2013]Detection of BRAF V.. ÆijªÁø 6107
   40           [³í¹®] [2013]Comparison of Direc.. ÆijªÁø 25295
¢º           [³í¹®] [Microarray]Peptide nucle.. ÆijªÁø 14331
   38           [³í¹®] [Clamp]Rapid and Sensitiv.. ÆijªÁø 22252
   37           [³í¹®] [ÆijªÁø Á¦Ç°»ç¿ë ³í¹®] EGFR µ¹¿¬º¯.. ÆijªÁø 3396
   36           [³í¹®] [ÆijªÁø Á¦Ç°»ç¿ë ³í¹®] Development .. ÆijªÁø 14168
   35           [³í¹®] [ÆijªÁø Á¦Ç°»ç¿ë ³í¹®] JHDM3A modul.. ÆijªÁø 1176
   34           [³í¹®] [PNA Chip vs DNA Chip ÀÓ»ó.. ÆijªÁø 4037
   33           [³í¹®] [ÆijªÁø ³í¹®¹ßÇ¥] PNA-mediated Re.. ÆijªÁø 8832
   32           [³í¹®] [ÆijªÁø Á¦Ç°»ç¿ë ³í¹®] ºñ¼Ò¼¼Æ÷Æó¾Ï¿¡.. ÆijªÁø 14487
   31           [³í¹®] [ÆijªÁø ³í¹® ¹ßÇ¥] PNA-Based Anti.. ÆijªÁø 1181
   30           [³í¹®] [ÆijªÁø ³í¹®¹ßÇ¥]Peptide nucleic .. ÆijªÁø 3904
 

< 1 2 3 >